“Our study, to our knowledge, is the first population-based study that investigates the association between working in cold environment and risk of developing RA among healthy individuals,” wrote Pingling Zeng, PhD, Institute of Environmental Medicine, Karolinska University, Stockholm, Sweden, and colleagues.
A post hoc analysis of the recent OPTIMA trial supports the current treat-to-target strategy for patients with early rheumatoid arthritis (RA) that is recommended by the American College of Rheumatology and the European League Against Rheumatism
Biologic disease-modifying antirheumatic drugs have been the cornerstone of therapy for patients with rheumatoid arthritis (RA) for more than a decade. Although highly effective, these therapies can be expensive and access to them may be limited for some patients.
Using Preference Phenotypes to Enhance Communication, Facilitate Treatment Decision-Making, and Personalize Care
“One of the biggest challenges in the management of RA is monitoring disease effectively, in order to avoid missing flare-ups,” said Dr Walker and colleagues, adding that the use of patient-reported outcomes to complement disease monitoring is recommended by the European League Against Rheumatism.
Upadacitinib Is Effective in Patients with Active RA with Inadequate Response to Conventional Synthetic DMARDs
This is an analysis of the double-blind, placebo-controlled period 1 of the randomized phase 3 study that evaluated upadacitinib in patients with inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).
The MONARCH trial showed that subcutaneous sarilumab was superior to adalimumab monotherapy in reducing disease activity and improving physical function in active rheumatoid arthritis. Patients who completed the initial double-blind phase in MONARCH continued to the open-label extension and received sarilumab monotherapy.
No Increased Cardiovascular Risk in Patients with RA Who Newly Initiated Tocilizumab versus Abatacept
Sarilumab, a human monoclonal antibody against interleukin-6 receptors, is currently approved for patients with moderate-to-severe rheumatoid arthritis (RA), based on efficacy and safety data from several clinical trials.
Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA
The analysis of the COMPACT trial sought to demonstrate noninferiority of tocilizumab alone versus tocilizumab plus methotrexate (MTX) in maintaining clinical response in patients with rheumatoid arthritis (RA) who achieve low disease activity (LDA) following treatment with tocilizumab plus MTX.
Page 1 of 9
Results 1 - 10 of 87
Results 1 - 10 of 87